The Wnt/β-catenin pathway in human fibrotic-like diseases and its eligibility as a therapeutic target

Overview of attention for article published in Molecular and Cellular Therapies, January 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)

Mentioned by

twitter: 1 X user

patent: 29 patents

Citations

dimensions_citation: 51 Dimensions

Readers on

mendeley: 71 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 29 patents that reference this research output.

Single-dose, ready-to-use injectable formulations

Grant US-11819499-B2

United States of America

Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors

Grant US-11780823-B2

United States of America

Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof

Grant US-11697649-B2

United States of America

Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway…

Grant US-11684615-B2

United States of America

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity, including 25 additional patents.